CD4+ T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapy [0.03%]
BCMA CAR-T细胞治疗相关的CAR-T细胞介导的免疫相关不良事件由CD4阳性T细胞引起
Matthew Ho,Luca Paruzzo,Julia Han Noll et al.
Matthew Ho et al.
B cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of multiple myeloma but can cause unique toxicities, including cranial nerve palsy, parkinsonism and enterocolitis, wh...
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma [0.03%]
多发性骨髓瘤中针对GPRC5D的T细胞衔接器的多模态抗原逃逸
Holly Lee,Sungwoo Ahn,Gerone A Gonzales et al.
Holly Lee et al.
Tumor-intrinsic adaptations with emerging resistant clones following T cell-targeted immunotherapies pose a major barrier to durable remissions in multiple myeloma. Through integrated genomic, transcriptomic and epigenomic interrogation of ...
Fractional flow reserve-guided percutaneous coronary intervention versus medical therapy for stable coronary artery disease: long-term results of the FAME 2 trial [0.03%]
基于血流储备分数的经皮冠状动脉介入治疗与稳定型冠心病的优化药物治疗：FAME 2研究长期结果分析
Carlos Collet,Thabo Mahendiran,William F Fearon et al.
Carlos Collet et al.
In patients with stable coronary artery disease (CAD), the long-term benefits of revascularization over medical therapy remain unclear. In the Fractional Flow Reserve versus Angiography for Multivessel Evaluation 2 trial, patients with hemo...
Genotype-stratified adjunctive dexamethasone for tuberculous meningitis in HIV-negative adults: a randomized controlled phase 3 trial [0.03%]
HIV阴性成人结核性脑膜炎分层加用甲基强的松龙的三期随机对照试验
Joseph Donovan,Nguyen Duc Bang,Huu Khanh Trinh Dong et al.
Joseph Donovan et al.
Adjunctive corticosteroids such as dexamethasone are recommended in tuberculous meningitis treatment, despite modest and heterogeneous survival benefit. Leukotriene A4 hydrolase (LTA4H) genotypes associate with distinct intracerebral inflam...
Tirzepatide on obstructive sleep apnea-related cardiometabolic risk: secondary outcomes of the SURMOUNT-OSA randomized trial [0.03%]
肽 tirzepatide 对阻塞性睡眠呼吸暂停相关的心代谢风险的影响：SURMOUNT-OSA 随机试验的次要结果
Atul Malhotra,Ronald Grunstein,Ali Azarbarzin et al.
Atul Malhotra et al.
Obstructive sleep apnea (OSA) is associated with obesity and cardiovascular risk. The SURMOUNT-OSA master protocol comprised two, 52-week, randomized, double-blind, placebo-controlled phase 3 studies (study 1 and study 2) and demonstrated a...
Mpox infection in pregnancy linked to high risk of adverse outcomes [0.03%]
怀孕期间感染马普托痘病毒会导致不良妊娠结局的风险增加
Karen O&#x;Leary
Karen O&#x;Leary
Circulating metabolites, genetics and lifestyle factors in relation to future risk of type 2 diabetes [0.03%]
循环代谢物、遗传和生活方式因素与2型糖尿病的未来风险之间的关系
Jun Li,Jie Hu,Huan Yun et al.
Jun Li et al.
The human metabolome reflects complex metabolic states affected by genetic and environmental factors. However, metabolites associated with type 2 diabetes (T2D) risk and their determinants remain insufficiently characterized. Here we integr...
A fasting-mimicking diet in patients with mild-to-moderate Crohn's disease: a randomized controlled trial [0.03%]
轻中度克罗恩病患者的模拟禁食饮食：一项随机对照试验
C Kulkarni,T Fardeen,J Gubatan et al.
C Kulkarni et al.
In healthy individuals, short cycles of a fasting-mimicking diet (FMD) decrease systemic inflammatory markers and improve metabolic health. Potential benefits of FMD have not been investigated in Crohn's disease (CD). We conducted an open-l...
Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosis [0.03%]
低毒新型恶唑烷酮类抗结核药物的研发与发现
Brendan M Crowley,Helena I Boshoff,Aidan Boving et al.
Brendan M Crowley et al.
Linezolid, an oxazolidinone, is a cornerstone of treatment regimens for highly drug-resistant tuberculosis but cannot be used in drug-susceptible disease because of toxicity. This toxicity results from inhibition of mammalian mitochondrial ...
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial [0.03%]
关于林可替尼和派姆单抗治疗免疫检查点抑制剂耐药的晚期实体瘤的I期临床试验
Timothy A Yap,Randy F Sweis,Ulka Vaishampayan et al.
Timothy A Yap et al.
Although immune checkpoint inhibitor therapies have revolutionized oncology, many cancers are unresponsive or develop resistance that involves transforming growth factor-β1 (TGFβ1). This multicenter, open-label, phase 1 study (DRAGON tria...